GlassScriptPhysician profile
Bradford A Bergman
NPI 1235130113
$2,187.28
in general payments reported to CMS, 2019-2025
26 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $72.11 · 2022: $308 · 2023: $713 · 2024: $232 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,158.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $275.99 | 2019-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $263.52 | 2019-2025 | Evenity, Repatha, Otezla |
| Corcept Therapeutics | $225.03 | 2022-2023 | Korlym |
| Astrazeneca Pharmaceuticals LP | $208.58 | 2019-2025 | Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $172.43 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| E.R. Squibb & Sons, L.L.C. | $170.61 | 2019-2024 | Eliquis |
| Novartis Pharmaceuticals Corporation | $111.84 | 2019-2024 | |
| Pfizer INC. | $107.13 | 2019-2023 | |
| Novo Nordisk INC | $100.06 | 2019-2025 | Wegovy |
| Exact Sciences Corporation | $72.26 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $64.54 | 2024-2025 | Veozah |
| Abbvie INC. | $53.11 | 2025 | |
| Xeris Pharmaceuticals, INC. | $42.14 | 2023 | Gvoke Hypopen, Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.24 | 2023 | Jardiance |
| Lundbeck LLC | $38.20 | 2019-2024 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $37.55 | 2019 | |
| Daiichi Sankyo INC. | $32.70 | 2024 | Injectafer |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.77 | 2023 | Rexulti |
| Lilly USA, LLC | $23.16 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.85 | 2022 | |
| Averitas Pharma INC. | $19.92 | 2023 | Qutenza |
| Verona Pharma, INC. | $19.80 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $18.86 | 2025 | |
| Depuy Synthes Sales INC. | $14.56 | 2019 | |
| Allergan, INC. | $14.41 | 2019 | |
| Acadia Pharmaceuticals INC | $14.02 | 2024 | Daybue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradford Bergman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.